Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Safety and Tolerability of Sustained Lipid-Lowering Therapy

Safety and Tolerability of Sustained Lipid-Lowering Therapy Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels Original Investigation Research REFERENCES elderly: looking beyond cost and regimen Cardiol. 2015;65(15):1539-1548. doi:10.1016/j.jacc. complexity. Am J Geriatr Pharmacother. 2011;9(1): 2015.02.017 1. Ference BA, Ginsberg HN, Graham I, et al. 11-23. doi:10.1016/j.amjopharm.2011.02.004 Low-density lipoproteins cause atherosclerotic 12. Bangalore S, Fayyad R, Messerli FH, et al. cardiovascular disease, 1. evidence from genetic, 7. Schwartz JB, Schmader KE, Hanlon JT, et al. Relation of variability of low-density lipoprotein epidemiologic, and clinical studies: a consensus Pharmacotherapy in older adults with cholesterol and blood pressure to events in patients statement from the European Atherosclerosis cardiovascular disease: report from an American with previous myocardial infarction from the IDEAL Society Consensus Panel. Eur Heart J. 2017;38(32): College of Cardiology, American Geriatrics Society, trial. Am J Cardiol. 2017;119(3):379-387. doi:10.1016/ 2459-2472. doi:10.1093/eurheartj/ehx144 and National Institute on Aging Workshop. JAm j.amjcard.2016.10.037 Geriatr Soc. 2019;67(2):371-380. doi:10.1111/jgs.15634 2. Navar-Boggan AM, Peterson ED, D’Agostino 13. Kim MK, Han K, Kim H-S, et al. Cholesterol RBS Sr, Neely B, Sniderman AD, Pencina MJ. 8. Khunti K, Danese MD, Kutikova L, et al. variability and the risk of mortality, myocardial Hyperlipidemia in early adulthood increases Association of a combined measure of http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Cardiology American Medical Association

Safety and Tolerability of Sustained Lipid-Lowering Therapy

JAMA Cardiology , Volume 4 (11) – Nov 25, 2019

Loading next page...
 
/lp/american-medical-association/safety-and-tolerability-of-sustained-lipid-lowering-therapy-BpMd5ijpkp
Publisher
American Medical Association
Copyright
Copyright 2019 American Medical Association. All Rights Reserved.
ISSN
2380-6583
eISSN
2380-6591
DOI
10.1001/jamacardio.2019.3528
Publisher site
See Article on Publisher Site

Abstract

Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels Original Investigation Research REFERENCES elderly: looking beyond cost and regimen Cardiol. 2015;65(15):1539-1548. doi:10.1016/j.jacc. complexity. Am J Geriatr Pharmacother. 2011;9(1): 2015.02.017 1. Ference BA, Ginsberg HN, Graham I, et al. 11-23. doi:10.1016/j.amjopharm.2011.02.004 Low-density lipoproteins cause atherosclerotic 12. Bangalore S, Fayyad R, Messerli FH, et al. cardiovascular disease, 1. evidence from genetic, 7. Schwartz JB, Schmader KE, Hanlon JT, et al. Relation of variability of low-density lipoprotein epidemiologic, and clinical studies: a consensus Pharmacotherapy in older adults with cholesterol and blood pressure to events in patients statement from the European Atherosclerosis cardiovascular disease: report from an American with previous myocardial infarction from the IDEAL Society Consensus Panel. Eur Heart J. 2017;38(32): College of Cardiology, American Geriatrics Society, trial. Am J Cardiol. 2017;119(3):379-387. doi:10.1016/ 2459-2472. doi:10.1093/eurheartj/ehx144 and National Institute on Aging Workshop. JAm j.amjcard.2016.10.037 Geriatr Soc. 2019;67(2):371-380. doi:10.1111/jgs.15634 2. Navar-Boggan AM, Peterson ED, D’Agostino 13. Kim MK, Han K, Kim H-S, et al. Cholesterol RBS Sr, Neely B, Sniderman AD, Pencina MJ. 8. Khunti K, Danese MD, Kutikova L, et al. variability and the risk of mortality, myocardial Hyperlipidemia in early adulthood increases Association of a combined measure of

Journal

JAMA CardiologyAmerican Medical Association

Published: Nov 25, 2019

References